Stock Market News for April 13, 2026
587 news published.
Biotech and Big Pharma Moves That Matter
Regeneron (REGN) scored two market‑moving updates: the EU approved Dupixent for young children with chronic spontaneous urticaria, widening its pediatric label, and the company announced a strategic radiopharma collaboration with Telix, signaling a push into targeted radioligand therapies that could reshape oncology revenues.
Revolution Medicines (RVMD) confirmed daraxonrasib’s Phase 3 survival gains in pancreatic cancer—an outcome that could be transformational if regulators sign off—and filed planned offerings of common stock and convertible senior notes to fund potential launch and commercialization (filing).
Allogene Therapeutics (ALLO) posted strong interim MRD results from ALPHA3 and separately filed a proposed $175 million common stock offering. Positive clinical momentum paired with near‑term capital raises can derisk timelines but may pressure near‑term equity—watch offer terms closely.
Cellectis (CLLS) released interim pivotal data for its Cema‑Cel allogeneic CAR‑T program showing encouraging efficacy and safety signals (details), a datapoint investors should weigh alongside other CAR‑T readouts.
Diagnostics, Devices and Strategic Deals
Danaher/Beckman Coulter Diagnostics (DHR) earned a CE mark for a rapid bacterial vs. viral assay delivering ~20‑minute results—an operational edge for hospitals that could accelerate diagnostic adoption in Europe (release).
Stryker (SYK) agreed to acquire Amplitude Vascular Systems, adding intravascular lithotripsy to its lineup—an M&A move that broadens product depth in a high‑growth vascular segment (details).
Penumbra (PEN) released STORM‑PE data showing computer‑assisted vacuum thrombectomy improved 90‑day functional outcomes versus anticoagulation alone—evidence that could broaden clinical adoption and commercial potential (study).
Quarterly Results, Capital Moves and Investor Events
Medtronic (MDT) set a date to report Q4 and fiscal 2026 results—earnings from this med‑tech bellwether often give clues on procedure volumes and hospital spending.
Cloudflare (NET) announced first quarter 2026 results and an investor day—investors will watch guidance on security and networking traction and the company's market outlook (details).
Magna International (MGA) set the date for its first quarter 2026 results webcast; auto suppliers' updates remain key for judging production and margin trends (webcast).
Venture Global (VG) announced timing for its Q1 2026 earnings release and conference call, useful for tracking LNG project milestones and financing progress (call details).
NextDecade (NEXT) scheduled its Q1 investor call—another event to watch for LNG project updates and capital plans (call details).
Energy, Exploration and Clean Tech
TotalEnergies (TTE) made a hydrocarbon discovery on the Moho license in the Republic of the Congo and signed a cooperation agreement with Türkiye Petroleum—exploration gains and regional ties that could shift reserve and development timelines (read, agreement).
Halliburton (HAL) secured a multibillion‑dollar unconventional completions contract from YPF in Argentina—visible backlog that backs Latin America revenue and margin strength (details).
Chevron (CVX) consolidated its Venezuela heavy oil position in an asset swap, tightening its upstream footprint in the region and potentially altering reserve allocations and development timelines (terms).
Bloom Energy (BE) and Oracle expanded a strategic partnership to deploy up to 2.8 GW of on‑site power to accelerate AI infrastructure build‑out. That kind of capacity deployment links clean energy systems directly to data‑center and AI demand—an emerging revenue channel investors should monitor.
Industrial Tech, Semiconductors and Connectivity
Supermicro (SMCI) introduced compact, energy‑efficient systems aimed at accelerating intelligent edge AI adoption—product launches that can expand TAM exposure as edge compute demand grows (announcement).
Microchip (MCHP) strengthened its ASA‑ML ecosystem via a collaboration with Sunny Smartlead, reinforcing camera and edge‑AI partnerships that feed semiconductor content growth (read).
Credo (CRDO) agreed to acquire DustPhotonics to accelerate expansion into silicon photonics and next‑generation optical connectivity—an inorganic step that could boost optical component content for hyperscalers and telecom suppliers (acquisition details).
Space, Defense and Emerging Tech
RTX (RTX) said Bell selected five RTX systems for the U.S. Army’s Future Long Range Assault Aircraft program—an important defense win that supports aerospace backlog and long‑cycle revenue visibility (details).
IonQ (IONQ) and the University of Maryland expanded their QLab collaboration to advance quantum networking and research, a development that could accelerate commercialization of quantum communications and boost IonQ’s ecosystem relevance (announcement).
Corporate Actions and Governance
Visa (V) commenced an exchange offer for Class B‑1 and Class B‑2 common stock, a corporate action that can affect share structure and voting dynamics; investors will watch participation levels and potential impacts on free float (exchange offer).
Ondas (ONDS) received an initial $68 million order under a $140 million strategic military engineering program—an immediate revenue win that can build a sustained defense backlog (details).
Consumer, Retail and Real‑Estate Signals
Roblox (RBLX) introduced age‑based accounts and expanded parental controls for users under 16, a product change that may influence engagement and monetization among younger cohorts (announcement).
Terreno Realty (TRNO) announced development completion in Hialeah, FL—an occupancy milestone that can feed near‑term NOI and leasing visibility (announcement).
Notable Small‑Cap and Early‑Stage Items to Watch
- Hoth Therapeutics (HOTH) reported positive HT‑VA CRADA data showing GDNF reprograms liver fat metabolism and outperforms semaglutide in preclinical markers—early science that could inform future metabolic programs (study).
- Kazia Therapeutics (KZIA) expanded its oncology platform with a first‑in‑class SETDB1 inhibitor drug development program—an R&D move that broadens its pipeline and long‑term value drivers (announcement).
- Cellectis (CLLS) — Cema‑Cel pivotal interim data (see above).
Stay ahead of the market with our list of today's most important stock news and financial updates. Whether you're a day trader, long-term investor, or market enthusiast, our news feed covers everything you need to know about publicly traded companies.
Our news feed is designed for investors who want to stay informed about the latest developments affecting their portfolio or watchlist. Whether you're researching potential investments, monitoring your current holdings, or simply staying up-to-date with market trends, our stock news page provides the information you need to make informed decisions.
What You'll Find on This Page:
- Breaking financial news and market-moving headlines
- FDA approvals and clinical trial results for biotech and pharma stocks
- Stock offerings, dividends, and other corporate actions
- Mergers, acquisitions, and strategic partnerships
- Business news affecting company performance and stock prices
- Easy-to-use tags for quick news categorization
- Stock tickers for instant company identification
- AI sentiment analysis to gauge market reaction
- Estimated impact scores to assess potential stock movement